Protalix BioTherapeutics Inc (AMEX:PLX)’s traded shares stood at 0.69 million during the last session, with the company’s beta value hitting -0.02.The PLX share’s 52-week high remains $3.10, putting it -3.33% down since that peak but still an impressive 72.67% since price per share fell to its 52-week low of $0.82. The company has a valuation of $238.55M, with an average of 0.88 million shares in intraday trading volume over the past 10 days and average of 728.60K shares over the past 3 months.
Protalix BioTherapeutics Inc (AMEX:PLX) trade information
The 5-day price performance for the stock is 5.26%, and 15.83% over 30 days. With these gigs, the year-to-date price performance is 59.57%. Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) saw shorts transact 0.74 million shares and set a 1.02 days time to cover.
Protalix BioTherapeutics Inc (PLX) estimates and forecasts
The rating firms project that company’s revenue will grow 63.34% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 21.6M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 23.1M.Earnings reports from the last fiscal year show that sales brought in 3.68M and 13.3M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 487.44% before jumping 73.63% in the following quarter.
PLX Dividends
Protalix BioTherapeutics Inc has its next earnings report out on 2025-Mar-16. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Protalix BioTherapeutics Inc (AMEX:PLX)’s Major holders
Protalix BioTherapeutics Inc insiders hold 13.44% of total outstanding shares, with institutional holders owning 6.02% of the shares at 6.95% float percentage. In total, 6.02% institutions holds shares in the company, led by MILLENNIUM MANAGEMENT LLC. As of 2024-06-30, the company held over 0.81 million shares (or 1.1106% of shares), all amounting to roughly $0.95 million.
The next major institution holding the largest number of shares is RENAISSANCE TECHNOLOGIES LLC with 0.8 million shares, or about 1.1016% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.94 million.
We also have Unified Series Trust-AUER GROWTH FUND and Bridgeway Funds, Inc.-Ultra-Small Company Market Fund as the top two Mutual Funds with the largest holdings of the Protalix BioTherapeutics Inc (PLX) shares. Going by data provided on Mar 31, 2025 , Unified Series Trust-AUER GROWTH FUND holds roughly 200.0 shares. This is just over 0.25% of the total shares, with a market valuation of $0.6 million. Data from the same date shows that the other fund manager holds a little less at 180.0, or 0.23% of the shares, all valued at about 0.54 million.
